Compare Novavax Inc (NVAX) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Sprott Uranium Miners ETF — how do they compare? Novavax Inc trades at $11.97 (market cap $1.82B), while Sprott Uranium Miners ETF trades at $46.31 (market cap $1.87B). The key difference: Novavax Inc and Sprott Uranium Miners ETF are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Sprott Uranium Miners ETF for 60 Days on average.
| NVAX | URNM | |
|---|---|---|
Market Cap | $1.82B | $1.87B |
Volume | 6,198,505 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $12.56 | $83.99 |
52-Week Low | $6.22 | $46.09 |
Typical Hold Time | 59 Days | 60 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
URNM (Sprott Uranium Miners ETF) trades at $47.87, down 4.83% today amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average indicators, though oscillators remain neutral. Recent news highlights uranium's long-term growth potential driven by AI energy demand and government nuclear investments, with spot uranium prices rising 21.25% over the past year according to Sprott Asset Management (September 2026).
The uranium sector shows strong fundamental tailwinds from nuclear energy expansion and AI power needs, but URNM's technical weakness suggests near-term volatility. Investment opportunity exists in uranium supply deficits and contracting growth, while risks include ETF concentration and commodity price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
